Advanced Filters
noise

Muellheim, Germany Clinical Trials

A listing of Muellheim, Germany clinical trials actively recruiting patients volunteers.

Found 11 clinical trials

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).

18 - 100 years of age Both Phase 3
M MedAlliance Clinical Team

SELUTION4BTK Trial

This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.

18 - 100 years of age Both Phase N/A
M MedAlliance Clinical Team

SELUTION4SFA Trial

This study aims to demonstrate the safety and efficacy of the SELUTION SLR™ 018 DEB compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).

18 - 100 years of age Both Phase N/A

Evolut™ EXPAND TAVR II Pivotal Trial

Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.

65 - 100 years of age Both Phase N/A
D Dr. Ivica Kristic, MD, PhD

LANDMARK Trial: a Randomised Controlled Trial of Myval THV

The primary objective of this study (LANDMARK) is to compare the safety and effectiveness of the Myval THV Series with Contemporary Valves (Sapien THV Series and Evolut THV Series) in patients with severe symptomatic native aortic valve stenosis. This study will be done in total 768 subjects (384:384, Myval THV …

18 - 100 years of age Both Phase N/A

The SELUTION DeNovo Study

A Prospective Randomized, Multi-center, International, Single-blind, Clinical trial compared the Selution DEB strategy versus DES strategy.

18 - 100 years of age Both Phase N/A
L Laurent Bertoletti, PhD

Pulmonary Embolism International THrOmbolysis Study-3

In this study, we will assess the efficacy and safety of a reduced dose of thrombolytic therapy given in addition to low-molecular-weight heparin in patients with intermediate-high-risk acute pulmonary embolism. Half of participants will receive thrombolytic treatment, while the other half will receive a placebo.

18 - 100 years of age Both Phase 3
B Barbara Shimada-Krouwer, RN

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.

18 - 90 years of age Both Phase N/A
M Martin Andrassy, Prof. Dr.

Trial to Assess the Safety and Efficacy of Sirolimus-Coated Balloon vs. Uncoated Standard Angioplasty for the Treatment of Below-the-knee Peripheral Arterial Disease

This study is a prospective, interventional, multicenter 1:1 randomized trial. The trial evaluates the safety and efficacy of the Magic Touch PTA sirolimus drug-coated balloon in comparison to the treatment with POBA (control device) in patients with advanced infrapopliteal artery disease.

18 - 100 years of age Both Phase N/A

Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care

This is a multicenter, non-randomized, non-interventional cohort study with prospective and retrospective collection of primary data on heart failure with reduced ejection fraction (HFrEF) patient treatment and care following a decompensation event in different types of Heart Failure Unit (HFU) or non-HFU centers across Germany.

18 - 100 years of age Both Phase N/A

Rewrite in simple language using AI